Effectiveness and Feasibility Associated with Switching to a Second or Third TNF Inhibitor in Patients with Psoriatic Arthritis: A Cohort Study from Southern Sweden.

Lars Erik Kristensen, Elisabeth Lie, Lennart Jacobsson, Robin Christensen, Philip J Mease, Henning Bliddal, Pierre Geborek

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskriftPeer review

26 Citeringar (SciVal)

Sammanfattning

Because new modes of action for the treatment of psoriatic arthritis (PsA) are emerging, it is important to understand the use of switching to a second or third antitumor necrosis factor (anti-TNF) agent. This study investigated drug survival and treatment response rates of patients with PsA undergoing second- and third-line anti-TNF therapy.
Originalspråkengelska
Sidor (från-till)81-87
TidskriftJournal of Rheumatology
Volym43
Utgåva1
DOI
StatusPublished - 2016
Externt publiceradJa

Ämnesklassifikation (UKÄ)

  • Reumatologi och inflammation

Fingeravtryck

Utforska forskningsämnen för ”Effectiveness and Feasibility Associated with Switching to a Second or Third TNF Inhibitor in Patients with Psoriatic Arthritis: A Cohort Study from Southern Sweden.”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här